An Official Website of the United States Government
Company Information:
Name:
THERMALIN DIABETES, INC.
Address:
10000 Cedar Avenue
CLEVELAND, OH 44106-
CLEVELAND, OH 44106-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Clinical Testing of an Insulin Analog
Award Year / Program / Phase:
2009 / STTR / Phase I
Agency:
HHS
Research Institution:
CASE WESTERN RESERVE UNIVERSITY
Abstract:
DESCRIPTION (provided by applicant): The central goal of insulin replacement therapy in the treatment of Type 1 diabetes mellitus (T1DM) is tight control of blood glucose concentration. This Phase I STTR application, submitted by Thermalin Diabetes, Inc.,
in conjunction with Case Western Reserve… More
Halogenated Insulin: a fast-acting, ultra stable analog.
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Bruce H. Frank
Award Amount:
$392,091.00
Abstract:
DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel rapid-acting insulin analog for the treatment of diabetes mellitus. Designated Insulin-Cl, our product is a derivative of insulin lispro
(the active component of HumalogTM)… More
A Novel 'Zinc-Stapled' Long-Acting Insulin Analog
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Bruce H. Frank
Award Amount:
$423,635.00
Abstract:
DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designated Insulin-ZN, our product is a derivative of human ins
ulin containing novel zinc-binding sites at… More
Optimized Receptor Binding Profile in an Ultra-Stable, Ultra-Rapid-Acting Insulin
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 617-695-0523
Award Amount:
$622,539.00
Abstract:
DESCRIPTION (provided by applicant): We seek to develop an ultra-fast, zinc-free insulin analog formulation for the treatment of diabetes mellitus. An ultra-fast pharmacokinetic-dynamic (PK/PD) profile promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion)… More
Chlorolog: Production and Testing of a Fast-Acting, Ultra-stable Insulin Analog
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 317-846-4233
Award Amount:
$4,469,515.00
Abstract:
DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( smart pumps ). A proprietary approach is proposed basedon the favorable physico-chemical properties… More
Manipulating Aromaticity: characterization of an ultra-rapid insulin analog
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 317-846-4233
Award Amount:
$601,274.00
Abstract:
DESCRIPTION (provided by applicant): We seek to develop an ultra-fast insulin analog formulation for the treatment of diabetes mellitus. Ultra-fast pharmacokinetic/dynamic (PK/PD) promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion; CSII) with enhanced… More